Search results for "dalit"

showing 10 items of 1091 documents

High statistics study of ƒ0(1500)s decay into ηη

1995

Abstract A partial wave analysis of the reaction p p →π o ηη has been performed, using a high quality, high statistics data set of 198,000 events. In addition to the ƒ 0 (1370), a second scalar resonance decaying into ηη, the ƒ 0 (1500), with mass m = (1505 ± 15) MeV and width Γ = (120 ± 30) MeV has to be introduced to describe the data.

Nuclear physicsPhysicsNuclear and High Energy PhysicsParticle physicsQuality (physics)Partial wave analysisScalar (mathematics)StatisticsDalitz plotResonancePhysics Letters B
researchProduct

Hidden and open $$\bar ss$$ production in $$\bar pp$$ annihilation at restannihilation at rest

1994

New branching ratios for\(\bar pp\) annihilation at rest into final states with a\(K\bar K\) pair or φ-meson are being measured with the Crystal Barrel detector at LEAR. The yield of φγ, relative to ωγ, appears to violate the OZI rule as strongly as φπ relative to ωπ.

Nuclear physicsPhysicsParticle physicsAnnihilationOZI ruleHigh Energy Physics::PhenomenologyDalitz plotHigh Energy Physics::ExperimentIl Nuovo Cimento A Series 11
researchProduct

$$N\bar N$$ annihilation at rest into five pions

1993

\(N\bar N\) annihilation at rest into five pions was studied in the ASTERIX spectrometer by stopping antiprotrons from LEAR in a H2 or D2 gas target. In\(\bar pp\) annihilations in H2 leading to the π+π−π+π−π0 final state, the invariant mass spectra of two, three, and four pions show no evidence for any new narrow states. In\(\bar pn \to \pi ^ + \pi ^ - \pi ^ + \pi ^ - \pi ^ - \) the difference of the four pion mass spectra recoiling against a π− and those recoiling against a π+ shows a resonance-like structure (“ζ (1480)”), confirming a previous analysis with a smaller event sample. The ζ (1480) mass is shown to depend strongly on the momentum of the spectator proton. In H2, we searched fo…

Nuclear physicsPhysicsParticle physicsPionAnnihilationPhysics and Astronomy (miscellaneous)MesonProtonBranching fractionMass spectrumDalitz plotEngineering (miscellaneous)OmegaZeitschrift f�r Physik C Particles and Fields
researchProduct

Evidence for two isospin zeroJ PC=2−+ mesons at 1645 and 1875 MeV

1996

Data on\(\bar pp \to \eta \pi ^0 \pi ^0 \pi ^0 \) taken at beam momenta of 1.2 and 1.94 GeV/c reveal evidence for twoI=0JPC=2−+ resonances inηππ. The first, at 1645±14(stat.)±15(syst.) MeV with width 180−21+40±25 MeV, decays toα2(1320)π withL=0. It may be interpreted as the\(q\bar q^1 \)D2 partner ofπ2(1670). A strong signal is also observed just above threshold inf2(1270)η withL=0. It is 11–22 times stronger than is expected for the high mass tail of the 1645 MeV resonance. It can be fitted as a second 2−+ resonance at 1875±20±35 MeV with width 200±25±45 MeV. A third resonance havingJPC=2++ is observed at 2135±20±45 MeV withΛ=250±25±45 MeV, decaying to botha2(1320)π andf2(1270)η withL=1. T…

Nuclear physicsPhysicsPhysics and Astronomy (miscellaneous)MesonIsospinZero (complex analysis)High massDalitz plotResonanceAtomic physicsRest frameBar (unit)Zeitschrift für Physik C: Particles and Fields
researchProduct

High-statistics analysis of $$\bar pp \to \pi ^0 \pi ^0 \pi ^0 $$ at restat rest

1994

Antiproton-proton annihilation at rest into 3π0 is analysed based on a data sample of about 500 000 high-quality 3π0 events. In this high-statistics Dalitz plot two structures in the region of π0π0 invariant masses of about 1500 MeV show up, a small band and a blob at higher masses. In a first attempt to describe the data two different models are used to parametrize the dynamical amplitudes leading to the same conclusion: the data require a 0+ + and also a 2+ + resonance in the 1500 MeV region.

Nuclear physicsRest (physics)PhysicsParticle physicsAnnihilationAmplitudePiDalitz plotInvariant (mathematics)Nuclear ExperimentResonance (particle physics)Bar (unit)Il Nuovo Cimento A Series 11
researchProduct

Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.

2014

Objective To analyze the feasibility of laparoscopic/robotic secondary cytoreductive surgery and hyperthermic intraperitoneal intra-operative chemotherapy (SCS + HIPEC) in a retrospective series of isolated platinum sensitive recurrent ovarian cancer. Methods We retrospectively evaluated a consecutive series of ovarian cancer patients with isolated platinum sensitive relapse. Isolated relapse was defined as the presence of a single nodule, in a single anatomic site. In all cases the presence of isolated relapse was assessed at pre-operative FDG-PET/CT scan, and confirmed with staging laparoscopy performed immediately before SCS + HIPEC. Results 84 women with platinum sensitive relapse recei…

OVARIAN CANEROrganoplatinum Compoundsmedicine.medical_treatmentdrug therapy/pathology/surgery/therapyCarcinoma Ovarian EpithelialMultimodal ImagingCohort StudiesObstetrics and gynaecologyNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsInfusions ParenteralNeoplasms Glandular and EpithelialLaparoscopyadministration /&/ dosageTomographyRandomized Controlled Trials as TopicOvarian Neoplasmsmedicine.diagnostic_testObstetrics and GynecologyGlandular and EpithelialMiddle AgedDebulkingCombined Modality TherapyIsolated platinum sensitive relapseX-Ray ComputedOxaliplatinPhase III as TopicOncologyFemalediagnostic usemedicine.drugmedicine.medical_specialtyInfusionsAged Antineoplastic Combined Chemotherapy Protocols; administration /&/ dosage Cisplatin; administration /&/ dosage Clinical Trials; Phase II as Topic Clinical Trials; Phase III as Topic Cohort Studies Combined Modality Therapy Female Fluorodeoxyglucose F18; diagnostic use Humans Hyperthermia; Induced; methods Infusions; Parenteral Middle Aged Minimally Invasive Surgical Procedures Multimodal Imaging Neoplasms; Glandular and Epithelial; drug therapy/pathology/surgery/therapy Organoplatinum Compounds; administration /&/ dosage Ovarian Neoplasms; drug therapy/pathology/surgery/therapy Positron-Emission Tomography Radiopharmaceuticals; diagnostic use Randomized Controlled Trials as Topic Retrospective Studies Tomography; X-Ray Computed ocal; pathologyocalmethodsClinical Trials Phase II as TopicMinimally invasive surgeryOvarian cancerFluorodeoxyglucose F18ParenteralmedicineHumansMinimally Invasive Surgical ProceduresClinical TrialsHyperthermiaAgedRetrospective StudiesCisplatinChemotherapySeries (stratigraphy)HIPECbusiness.industryPhase II as TopicInducedHyperthermia Inducedmedicine.diseaseOxaliplatinSurgeryRoboticSettore MED/40 - GINECOLOGIA E OSTETRICIAClinical Trials Phase III as TopicPositron-Emission TomographyLaparoscopypathologyNeoplasm Recurrence LocalCisplatinRadiopharmaceuticalsbusinessOvarian cancerTomography X-Ray Computed
researchProduct

Iconography and monumental art in "feodal space" from the 10th to the 12th century : the depiction of the Three Kings and its spread

2012

This dissertation deals with the iconography of the Three Kings from the Xth to the XIIth century, by means of a study of its adaptation on monumental decoration in Latin Europe, so as to unravel how it was adapted by feudal society. In order to do so, the first question is that of the new royal status acquired in the Xth century by the Magi from the Gospel of Matthew, analyzed thanks to the concept of “ruler figure” that emerged at the time and was depicted by Marc Bloch in Les Rois thaumaturges (1924) and Ernst Kantorowicz in the The King’s Two Bodies (1957). The aim is to define where the newly defined Three Kings stand in the intricate network of “ties between man and man” theorized by …

Occident latinWise MenLatin OccidentFeudalismArt monumentalMagiSpace[SHS.RELIG] Humanities and Social Sciences/Religions[ SHS.ART ] Humanities and Social Sciences/Art and art history[SHS.ART]Humanities and Social Sciences/Art and art history1000-1200RoyautéChristian iconographyRois magesFéodalité[SHS.RELIG]Humanities and Social Sciences/ReligionsKingshipArchitectural decorationEspace[SHS.ART] Humanities and Social Sciences/Art and art history[ SHS.RELIG ] Humanities and Social Sciences/ReligionsÉpiphanieIconographie chrétienne
researchProduct

Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

2015

Abstract Purpose: To investigate the value of the metabolic tumor response assessed with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), compared with clinicobiologic markers to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in women with triple-negative breast cancer (TNBC). Experimental Design: Fifty consecutive women with TNBC and an indication for NAC were prospectively included. Different pretreatment clinical, biologic, and pathologic biomarkers, including SBR grade, the Ki-67 proliferation index, androgen receptor expression, EGF receptor (EGFR), and cytokeratin 5/6 staining, were assessed. Tumor glucose metabolism at baseline and its chan…

OncologyAdultCancer Researchmedicine.medical_specialtyPathologyProliferation indexmedicine.medical_treatmentBiopsyTriple Negative Breast NeoplasmsBreast cancerFluorodeoxyglucose F18Internal medicineBiopsyAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansEpidermal growth factor receptorTriple-negative breast cancerNeoadjuvant therapyAgedNeoplasm StagingChemotherapymedicine.diagnostic_testbiologybusiness.industryOdds ratioMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyNeoadjuvant TherapyTumor BurdenGlucoseTreatment OutcomeOncologyROC CurveLymphatic MetastasisPositron-Emission Tomographybiology.proteinFemaleNeoplasm GradingbusinessTomography X-Ray ComputedBiomarkersClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (pCR) after primary chemotherapy.

2009

Abstract Learning Objectives After completing this course, the reader will be able to: Summarize the main risk factors for relapse in patients with T4 breast cancer after neoadjuvant chemotherapy.Evaluate the role of hormone receptors and HER-2 as determinants of risk of relapse after neoadjuvant treatment.Compare the difference in outcomes between patients who achieve less than pCR in relation to receptor status. This article is available for continuing medical education credit at CME.TheOncologist.com. Purpose. Pathological complete response (pCR) to primary chemotherapy is the main determinant for improved disease-free survival (DFS) and overall survival (OS). The primary endpoints of ou…

OncologyAdultCancer Researchmedicine.medical_specialtyTime FactorsSettore MED/06 - Oncologia MedicaReceptor ErbB-2Breast NeoplasmsVinorelbineDisease-Free SurvivalBreast cancerTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPathologicalMastectomyAgedNeoplasm StagingCisplatinStage IIIB breast cancerNeoadjuvant chemotherapyPathological responseLong-term outcomesbusiness.industryRadiotherapy DosageMiddle Agedmedicine.diseasePrognosisCombined Modality TherapySurvival RateRegimenTreatment OutcomeOncologyHormone receptorLymphatic MetastasisFemaleLymph Nodesbusinessmedicine.drugEpirubicinFollow-Up StudiesThe oncologist
researchProduct

Neoadjuvant therapy for breast cancer

2019

Objective: To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I–III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area. Methods: Data from the High Resolution Study conducted in 7 Italian cancer registries were used; they are a representative sample of incident cancers in the study period (2009–2013). Included were 3546 women aged <85 years (groups <50, 50–69, 70–64, and 75+) with stage I–III breast cancer at diagnosis who underwent surgery. Women were classified as receiving NT if they received chemotherapy, target therapy, and/or hormone therapy before the first surgical treatment. Logistic…

OncologyAdultCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBreast NeoplasmsSettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineBreast cancerBreast cancerInternal medicineCancer screeningmedicineBiomarkers TumorOdds RatioMammographyHumans030212 general & internal medicineneoadjuvant therapyNeoadjuvant therapyTriple-negative breast cancerTumor markerCancer stagingAgedNeoplasm StagingAged 80 and overmedicine.diagnostic_testGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyCancer registryTreatment OutcomeOncology030220 oncology & carcinogenesisFemalemultidisciplinaryMammography
researchProduct